Document:

Amended and Restated Investors' Rights Agreement dated February 7, 2005

 Exhibit 4.2 
  
 HEMOSENSE, INC. 
  

  
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
  
 February 7, 2005 
  

 HEMOSENSE, INC. 
  
 AMENDED AND RESTATED 
  
 INVESTOR RIGHTS AGREEMENT 
  
 THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of February 7, 2005, among HemoSense, Inc., a Delaware
corporation (the “Company”), the holders of the Company’s Series A-2 Preferred Stock (the “Series A-2 Investors”) listed on Exhibit A hereto, the holders of the Company’s Series B-2 Preferred Stock (the
“Series B-2 Investors”) listed on Exhibit B hereto, the holders of the Company’s Series C-2 Preferred Stock (the “Series C-2 Investors”) listed on Exhibit C hereto, and the purchasers of the Company’s
Series C-3 Preferred Stock listed on Exhibit D hereto, including each “Additional Purchaser” as defined in the Series C-3 Preferred Stock Purchase Agreement, of even date herewith, who has executed a counterpart signature page
hereto which sets forth such Additional Purchaser’s name and address (the “Series C-3 Investors” and collectively with the Series A-2 Investors, the Series B-2 Investors and the Series C-2 Investors, the “Investors”) and
their transferees (as permitted herein). 
  
 Recitals

  
 WHEREAS, the Company and certain Investors are parties to
that certain Amended and Restated Investor Rights Agreement dated June 10, 2004 (the “Prior Agreement”), pursuant to which the Series A-1 Investors, Series B-1 Investors and Series C-1 Investors (all as defined in the “Prior
Agreement”) have certain rights regarding registration of the Company’s securities under the Securities Act of 1933, as amended (“Registration Rights”), certain preemptive rights regarding the Company’s equity offerings
(“Preemptive Rights”), certain rights to information (“Information Rights”) and certain voting rights (“Voting Rights”); 
  
 WHEREAS, pursuant to Section 6.3 of the Prior Agreement, the holders of a majority of the Registrable Securities (as defined in the Prior Agreement) may
consent to an amendment of the Prior Agreement; 
  
 WHEREAS,
pursuant to Section 2.2 of the Series C-2 Preferred Stock Purchase Agreement (the “Series C-2 Stock Purchase Agreement”) dated June 10, 2004, the Series A-1 Investors, Series B-1 Investors, and Series C-1 Investors elected to exercise
their Exchange Right under Section 2.1 of the Series C-2 Stock Purchase Agreement and thereby became holders of Series A-2, Series B-2, and Series C-2; 
  
 WHEREAS, the Company and the Series C-3 Investors have entered into a Series C-3 Preferred Stock Purchase Agreement of date even herewith; 
  
 WHEREAS, the Company, the Series A-2 Investors, the Series B-2 Investors, and
the Series C-2 Investors wish to amend and restate the Prior Agreement to give the Series C-3 Investors the Registration Rights, Preemptive Rights, Information Rights and Voting Rights described in this Amended and Restated Investor Rights
Agreement; and 

 WHEREAS, the holders of a majority of the Registrable Securities have consented to this amendment and
restatement of the Prior Agreement; 
  
 NOW, THEREFORE, the
parties agree as follows: 
  
 SECTION 1 
 DEFINITIONS 
  
 1.1 Certain Definitions. Hereafter, in this Agreement the following terms shall have the following respective meanings: 
  
 “Commission” shall mean the Securities and Exchange Commission or
any other federal agency at the time administering the Securities Act. 
  
 “Common Stock” shall mean the Company’s common stock, no par value per share. 
  
 “Conversion Stock” shall mean the shares of the Company’s common stock issued or issuable pursuant to conversion of the Preferred Stock.

  
 “Exempt Issuances” shall mean (i) the sale or
issuance of equity securities in the Company’s Initial Public Offering, (ii) the sale or issuance from and after March 4, 1997 of up to 3,800,000 shares of Common Stock to officers, directors and employees of, and consultants to, the Company
pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements approved by the Company’s Board of Directors, including upon exercise of options granted pursuant to any such plan or arrangement,
(iii) up to 180,000 shares issued upon the exercise of warrants held by Innovative Medical Product Consultants, GmbH as of the date hereof or issuable pursuant to that certain Non-Exclusive Sales Representative and Services Agreement dated November
12, 2002, (iv) the sale or issuance of the Preferred Stock or the issuance of Conversion Stock upon conversion of the Preferred Stock, (v) securities issuable upon exercise of warrants issued in connection with secured debt agreements approved by
the Board and (vi) equity securities issued in connection with a stock split, stock dividend or recapitalization of the Company. 
  
 “Holder” or “Holders” shall mean any Investor holding Registrable Securities (including Preferred Stock) and any Person holding
Registrable Securities to whom the rights under this Agreement have been transferred in accordance with Section 2.11 hereof. 
  
 “Initial Public Offering” shall mean a firm underwritten public offering by the Company of its Common Stock, with net proceeds of at least
$15,000,000 and with a price per share of at least $7.00, after giving effect to any stock split, stock dividend, stock combination or other recapitalization. 
  

 -2- 

 “Initiating Holders” shall mean any Investors, or transferees of Investors under Section 2.11
hereof, who in the aggregate are Holders of greater than 50% of the Registrable Securities. 
  
 “Person” shall mean any individual, firm, company, corporation, unincorporated association, partnership, trust, joint venture or other entity, and shall include any successor (by merger or otherwise) of such
entity. 
  
 “Preferred Stock” shall mean the Series A-2,
Series A-3, Series B-2, Series B-3, Series C-2 and Series C-3 Preferred Stock of the Company. 
  
 “Registrable Securities” shall mean (i) the Conversion Stock and (ii) any Common Stock of the Company issued or issuable in respect of the Conversion Stock upon any stock split, stock dividend,
recapitalization, or similar event, or any Common Stock otherwise issued or issuable with respect to the Preferred Stock; provided, however, that shares of Common Stock or other securities shall be treated as Registrable Securities
only if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, whether in a registered offering, Rule 144 transaction or otherwise, or (B) sold in a
transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale. 
  
 The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 
  
 “Registration Expenses” shall mean all expenses, except as
otherwise stated in Section 2.5, incurred by the Company in complying with Sections 2.1, 2.2 and 2.3 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of
counsel for the Company, blue sky fees and expenses, the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company, which shall be paid in any event by the
Company) and the reasonable fees and disbursements of one counsel for all Holders, in any registration pursuant to Sections 2.1, 2.2 and 2.3 hereof. 
  
 “Restricted Securities” shall mean the securities of the Company not available for sale under Rule 144(k) of the Securities Act. 
  
 “Securities Act” shall mean the Securities Act of 1933, as amended,
or any similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
  
 “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the securities registered
by the Holders. 
  

 -3- 

 “Shares” held by any Person shall mean all shares of the Company’s Preferred Stock
(calculated on an as-converted basis) and shares of Common Stock held by such Person. 
  
 SECTION 2 
 REGISTRATION RIGHTS 
  
 2.1 Requested Registration. 
  
 (a) Request for Registration. If the Company shall receive from Initiating Holders a written request that the
Company effect any registration, qualification or compliance with respect to not less than thirty percent (30%) of the shares of Registrable Securities, or any lesser number of shares if the anticipated aggregate offering price, net of underwriting
discounts and commissions, would exceed $250,000, the Company shall: 
  
 (i) promptly give written notice of the proposed registration, qualification or compliance to all other Holders; and 
  
 (ii) as soon as practicable, use its best efforts to effect such registration, qualification or compliance (including, without limitation, appropriate
qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request
as are specified in a written request received by the Company within twenty (20) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any
such registration, qualification or compliance pursuant to this Section 2.1: 
  
 (A) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already
subject to service in such jurisdiction and except as may be required by the Securities Act; 
  
 (B) Prior to the earlier of (i) six months after the effective date of the registration statement in respect of the initial public offering of the Company’s securities and (ii) October 31, 2005; 
  
 (C) During the period starting with the date sixty (60) days prior to the
Company’s estimated date of filing of, and ending on the date six (6) months immediately following the effective date of, any registration statement pertaining to securities of the Company in which each Initiating Holder was entitled to
participate to the fullest extent it desired pursuant to Section 2.2 (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good faith all
reasonable efforts to cause such registration statement to become effective; 
  

 -4- 

 (D) If the Company has effected two such registrations pursuant to this subparagraph 2.1(a), and each
such registration has been declared or ordered effective; 
  
 (E)
If the Company shall furnish to such Holders a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders
for a registration statement to be filed at such time, in which case the Company’s obligation to use its best efforts to register, qualify or comply under this Section 2.1 shall be deferred for a period not to exceed sixty (60) days from the
date of receipt of written request from the Initiating Holders, provided that such right to delay a request may not be exercised by the Company more than once in any twelve-month period. 
  
 Subject to the foregoing clauses (A) through (E), the Company shall file a registration statement covering the Registrable
Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders. 
  
 (b) Underwriting. In the event that a registration pursuant to Section 2.1 is for a registered public offering involving an underwriting, the
Company shall so advise the Holders as part of the notice given pursuant to Section 2.1(a)(i). In such event, the right of any Holder to registration pursuant to Section 2.1 shall be conditioned upon such Holder’s participation in the
underwriting arrangements required by this Section 2.1(b), and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested shall be limited to the extent provided herein. 
  
 The Company shall (together with all Holders proposing to distribute their
securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders, but subject to the Company’s
reasonable approval. Notwithstanding any other provision of this Section 2.1, if the managing underwriter advises the Company in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall
so advise all holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders in proportion, as nearly as practicable, to the
respective amounts of Registrable Securities held by such Holders at the time of filing the registration statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included
in such registration. To facilitate the allocation of Registrable Securities to be included in the registration and underwriting in accordance with the above provisions, the Company or the underwriters may round the number of shares of Registrable
Securities allocated to any Holder to the nearest one hundred (100) shares. 
  
 If any Holder of Registrable Securities disapproves of the terms of the underwriting, such Person may elect to withdraw therefrom by written notice to the Company, the managing underwriter and the Initiating Holders.
The Registrable Securities and/or other securities so withdrawn shall also be withdrawn from registration. 
  

 -5- 

 2.2 Company Registration. 
  
 (a) Notice of Registration. If at any time or from time to time the Company shall determine to register any of its
equity securities, either for its own account or the account of a security holder or holders, other than (i) a registration relating solely to employee benefit plans, or (ii) a registration relating solely to a Rule 145 transaction, the Company
will: 
  
 (i) promptly give to each Holder written notice
thereof; and 
  
 (ii) include in such registration (and any
related qualification under blue sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within twenty (20) days after mailing of such written notice by
the Company, by any Holder. 
  
 (b) Underwriting. If the
registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event the right of any
Holder to registration pursuant to Section 2.2 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the managing
underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 2.2, if the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the
managing underwriter may limit the Registrable Securities to be included in such registration. The Company shall so advise all Holders and other holders distributing their securities through such underwriting and the number of shares of Registrable
Securities that may be included in the registration and underwriting shall be allocated among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the
registration statement. In any offering subsequent to the Initial Public Offering, the number of Registrable Securities to be included may not be reduced pursuant to this paragraph to less than 30% of the total number of shares included in the
registration statement, and in the Initial Public Offering, Holders may be excluded entirely so long as no other selling stockholders are included in the registration statement. To facilitate the allocation of Registrable Securities to be included
in the registration and underwriting in accordance with the above provisions, the Company may round the number of shares of Registrable Securities allocated to any Holder or holder to the nearest one hundred (100) shares. If any Holder or holder
disapproves of the terms of any such underwriting, he may elect to withdraw therefrom by written notice to the Company and the managing underwriter. Any securities excluded or withdrawn from such underwriting shall be withdrawn from such
registration. 
  
 (c) Right to Terminate Registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include Registrable Securities in such
registration. 
  

 -6- 

 2.3 Registration on Form S-3. 
  
 (a) If any Holder or Holders of at least 20% of the then-outstanding
Registrable Securities request that the Company file a registration statement on Form S-3 (or any successor form to Form S-3) for a public offering of shares of the Registrable Securities the reasonably anticipated aggregate offering price to the
public of which, net of underwriting discounts and commissions, would exceed $250,000, and the Company is a registrant entitled to use Form S-3 to register the Registrable Securities for such an offering, the Company shall give prompt written notice
of such proposed registration to all Holders and shall use its best efforts to cause the Registrable Securities, and any other Registrable Securities held by others who so notify the Company in writing within twenty (20) days after mailing of such
written notice by the Company that they wish to participate, to be registered for the offering on such form and to cause the Registrable Securities to be qualified in such jurisdictions as the Holder or Holders may reasonably request;
provided, however, that the Company shall not be required to effect more than one registration pursuant to this Section 2.3 in any six (6) month period. The substantive provisions of Section 2.1(b) shall be applicable to each
registration initiated under this Section 2.3. 
  
 (b)
Notwithstanding the foregoing, the Company shall not be obligated to take any action pursuant to this Section 2.3: (i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; (ii) during the period starting with the date sixty (60) days prior
to the Company’s estimated date of filing of, and ending on the date three (3) months (or, with respect to the Initial Public Offering, six (6) months) immediately following, the effective date of any registration statement pertaining to
securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan) in which the Holders are able to include Registrable Securities to the fullest extent they desire, provided
that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; or (iv) if the Company shall furnish to such Holder a certificate signed by the President of the Company stating
that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed at such time, then the Company’s obligation to use its best efforts to file
a registration statement shall be deferred for a period not to exceed sixty (60) days from the receipt of the request to file such registration by such Holder, provided that such right to delay a request may not be exercised by the Company more than
once in any twelve-month period. 
  
 2.4 Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not enter into any agreement granting any holder or prospective holder of any securities of the Company registration rights with respect to such
securities unless (i) the rights of such holders to participate in Company offerings are subordinate to the rights of the Holders under Section 2.2 and such holder shall have no right to make a demand registration that could result in such
registration statement being declared effective prior to October 31, 2004; or (ii) the Holders of at least 66 2/3% of the total then outstanding Registrable Securities consent to the grant of such registration rights. 
  

 -7- 

 2.5 Expenses of Registration. All Registration Expenses incurred in connection with
registrations pursuant to Sections 2.1, 2.2 and 2.3 shall be borne by the Company. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of such securities pro rata, on
the basis of the number of shares so registered. 
  
 2.6
Registration Procedures. In the case of each registration, qualification or compliance effected by the Company pursuant to this Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration,
qualification and compliance and as to the completion thereof. At its expense the Company will: 
  
 (a) Prepare and file with the Commission a registration statement with respect to such securities and use its best efforts to cause such registration
statement to become effective as soon as practicable after filing and remain effective until the earlier of (i) one hundred eighty (180) days from the date of filing and (ii) the date on which the distribution described in the registration statement
has been completed; provided, however, that if, in the case of clause (i), the use of the registration statement was suspended under Section 2.6(e), such 180 days shall be extended by the number of days for which the use of the
registration statement was suspended; 
  
 (b) Furnish to the
Holders participating in such registration and to the underwriters of the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus, final prospectus and such other documents as such Holders
or underwriters may reasonably request in order to facilitate the public offering of such securities; 
  
 (c) As expeditiously as possible prepare and file with the Commission any amendments and supplements to the registration statement and the prospectus
included in the registration statement as may be necessary to comply with the Securities Act and keep the registration statement effective, in the case of a firm commitment underwritten public offering, until each underwriter has completed the
distribution of all securities purchased by it and, in the case of any other offering, until the earlier of the sale of all Registrable Shares covered thereby or 180 days after the effective date thereof; provided, however, that in the
event the use of the registration statement was suspended under Section 2.6(e), such 180 days shall be extended by the number of days for which the use of the registration statement was suspended; 
  
 (d) As expeditiously as possible use its best efforts to register or qualify
the Registrable Shares covered by the registration statement under the securities or blue sky laws of such states as the selling Holders shall reasonably request, and do any and all other acts and things that may be necessary or desirable to enable
the selling Holders to consummate the public sale or other disposition in such states of the Registrable Shares owned by the selling Holders; provided, however, that the Company shall not be required in connection with this paragraph
(d) to qualify as a foreign corporation or execute a general consent to service of process in any jurisdiction; and 
  
 (e) If the Company has delivered preliminary or final prospectuses to the selling Holders and after having done so the prospectus is amended to comply
with the requirements of the Securities Act, the Company shall promptly notify the selling Holders and, if requested, the 

  

 -8- 

 
selling Holders shall immediately cease making offers of Registrable Shares and return all prospectuses to the Company. The Company shall file an amendment
or prospectus supplement as soon as practicable (but in no event later than ten (10) days after the date of such request) and thereafter promptly provide the selling Holders with revised prospectuses and, following receipt of the revised
prospectuses, the selling Holders shall be free to resume making offers of the Registrable Shares. 
  
 2.7 Indemnification. 
  
 (a) The Company shall indemnify each Holder, each of its officers, directors, partners, accountants, legal counsel and agents, and each Person
controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 2, and each underwriter, if any, and each Person who controls
any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced
or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto,
incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
in which they were made, not misleading, or any violation or alleged violation by the Company of the Securities Act or any rule or regulation promulgated under the Securities Act, the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), state securities or blue sky laws or otherwise applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers and directors, and each
Person controlling such Holder, each such underwriter and each Person who controls any such underwriter, as incurred, for any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim,
loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue
statement or omission made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder, controlling Person or underwriter and stated to be specifically for use therein.

  
 (b) Each Holder shall, if Registrable Securities held by such
Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors, officers, accountants, legal counsel and agents, each underwriter, if any, of the
Company’s securities covered by such a registration statement, each Person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of its officers, directors,
partners, accountants, legal counsel and agents, and each Person controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or
based on any untrue statement (or alleged untrue statement) of a material fact 

  

 -9- 

 
contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company, such Holders, such directors, officers, Persons, underwriters or control Persons, as incurred, for any legal or
any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder
and stated to be specifically for use therein. Notwithstanding the foregoing, the liability of each Holder under this subsection (b) shall be limited in an amount equal to the net proceeds received from the sale of Registrable Securities offered and
sold by such Holder pursuant to such registration statement, and shall not apply to amounts paid in settlement of any such damage or liability if such settlement was effected without the consent of 66% of the Holders. 
  
 (c) Each party entitled to indemnification under this Section 2.7 (the
“Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and
shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the
Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense; provided, however, that the Indemnified Party (together with all other
Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the
counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other party represented by such counsel in such proceeding; and provided further
that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2 unless, and only to the extent that, the failure to give such notice is materially
prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 
  
 (d) In order to provide for just and equitable contribution to joint
liability under the Securities Act in any case in which either (i) any Holder exercising rights under this Agreement, or any controlling Person of such Holder, makes a claim for indemnification pursuant to this Section 2.7 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding
the fact that this Section 2.7 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling Holder or any such controlling Person in 

  

 -10- 

 
circumstances for which indemnification is provided under this Section 2.7, then, and in each such case, the Company and such Holder will contribute to the
aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that such Holder is responsible for the portion represented by the percentage that the public offering price of its
Registrable Securities offered by and sold under the registration statement bears to the public offering price of all securities offered by and sold under such registration statement, and the Company and the other selling Holders are responsible for
the remaining portion; provided, however, that in any such case, (A) no such Holder will be required to contribute any amount in excess of the net proceeds received from the sale of all such Registrable Securities offered and sold by
such Holder pursuant to such registration statement; (B) no such Holder shall be required to contribute to any amount paid in settlement if such settlement was effected without the consent of 66% of the Holders; and (C) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 (e) The obligations of the Company and Holders under this Section 2.7 shall
survive the completion of any offering of Registrable Securities in a registration statement, and otherwise. 
  
 2.8 Termination of Registration Rights. The rights granted pursuant to this Agreement, to the extent not earlier terminated by the terms
hereof, shall terminate as to any Holder (i) five (5) years after the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale of Common Stock for the account of
the Company to the public, or (ii) at such time after the Company’s Initial Public Offering as all Registrable Securities held by such Holder can be sold without compliance with the registration requirements of the Securities Act in any
one-month period pursuant to Rule 144 (including Rule 144(k)) promulgated thereunder and such Holder owns less than 1% of the then outstanding Registrable Securities. 
  
 2.9 Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall
furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may reasonably request in writing and as shall be reasonably
required in connection with any registration, qualification or compliance referred to in this Section 2. 
  
 2.10 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission that may at any
time permit the sale of the Restricted Securities to the public without registration, after such time as a public market exists for the Common Stock of the Company, the Company agrees: 
  
 (a) To make and keep public information available, as those terms are understood and defined in Rule 144 under the
Securities Act, at all times after the effective date that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 
  

 -11- 

 (b) To file with the Commission in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 
  
 (c) So long as an Investor owns any Shares that are Restricted Securities, to furnish to the Investor forthwith upon request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an offering of its securities to the general public),
and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and
other information in the possession of or reasonably obtainable by the Company as such Investor may reasonably request in availing itself of any rule or regulation of the Commission allowing an Investor to sell any such securities without
registration. 
  
 2.11 Transfer of Registration
Rights. The rights to cause the Company to register Registrable Securities granted Investors under Sections 2.1, 2.2 and 2.3 may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities
by an Investor, provided that the Company is given notice of the transfer or assignment and: (a) such transfer may otherwise be effected in accordance with applicable securities laws, and (b) either (i) such assignee or transferee acquires at least
the lesser of (A) 100,000 shares of Preferred Stock and/or Common Stock issued upon conversion thereof (appropriately adjusted for recapitalizations) and (B) all of such Shares held by the Investor or (ii) such transferee is a partner, member,
shareholder or an Affiliate of the Investor. 
  
 Notwithstanding
the foregoing, the rights to cause the Company to register Registrable Securities may be assigned to (x) any partner, member, shareholder or Affiliate of an Investor, including any entity controlling, controlled by or under common control of such
Investor, (y) a limited partnership the limited partners of which are employees of Affiliates of the ultimate parent company of the general partner of such limited partnership, or (z) additional limited partnerships or other entities held directly
or indirectly by employees of Affiliates of the ultimate parent company of such entities, provided written notice thereof is promptly given to the Company and the transferee agrees to be bound by the provisions of this Agreement without compliance
with item (ii) above. “Affiliates” shall include, with respect to an Investor which is a partnership or limited liability company, its partners, members, former partners, former members or an affiliated entity managed by the same manager
or managing partner or management company, or managed or owned by an entity controlling, controlled by, or under common control with, such manager or managing partner or management company. 
  
 2.12 Lockup Agreement. Each Holder agrees, in connection with
the initial public offering of the Company’s securities, and one additional follow-on public offering of the Company’s securities occurring within one year of such initial public offering, upon request of the Company or the underwriters
managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any 

  

 -12- 

 
Registrable Securities (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may
be, for such period of time (not to exceed one hundred eighty (180) days in the case of the initial public offering and ninety (90) days in the case of such follow-on public offering) (the “Lockup Period”) from the effective date of such
registration as may be requested by the underwriters, provided that (i) similar lockup agreements are entered into by each of the Company’s officers and directors, each Holder holding not less than 10% of the Company’s outstanding capital
stock (including shares of Common Stock issuable upon the conversion of Shares, or other convertible securities, or upon the exercise of options, warrants or rights), and (ii) transfers to donees and to shareholders, members, partners or affiliates
of the transferor shall be permitted if the transferee agrees in writing to abide by the same lockup restrictions. In order to enforce the provisions of this Section 2.12, the Company may impose stop-transfer instructions with respect to the
securities of the Company held by each Holder until the end of the Lockup Period. This Section 2.12 shall be binding on all transferees or assignees of Registrable Securities, whether or not such Persons are entitled to registration rights pursuant
to Section 2.1, Section 2.2 or Section 2.3. 
  
 2.13 Merger,
Etc. The Company shall not, directly or indirectly, enter into any merger, consolidation or reorganization in which the Company shall not be the surviving corporation unless the proposed surviving corporation shall, prior to such merger,
consolidation or reorganization, agree in writing to assume the obligations of the Company under this Agreement, and for that purpose references hereunder to “Registrable Securities” shall be deemed to be references to the securities which
the Holders would be entitled to receive in exchange for Registrable Securities under any such merger, consolidation or reorganization; provided, however, that the provisions of this Section 2.13 shall not apply in the event of any
merger, consolidation or reorganization in which the Company is not the surviving corporation if all Holders are entitled to receive in exchange for their Registrable Securities consideration consisting solely of (a) cash, (b) securities of the
acquiring corporation which may be immediately sold to the public without registration under the Securities Act, or (c) securities of the acquiring corporation which the acquiring corporation has agreed to register within sixty (60) days of
completion of the transaction for resale to the public pursuant to the Securities Act. 
  
 SECTION 3 
 PREEMPTIVE RIGHT ON COMPANY ISSUES 
  
 3.1 Right of First Refusal. The Company hereby grants to each
Investor holding at least 25% of the Registrable Securities owned by such Investor as of the date of this Agreement (excluding all shares (the “Forced Conversion Shares”) of Common Stock issued on automatic conversion of such Preferred
Stock pursuant to Section C(2)(c) of Article Four of the Company’s Amended and Restated Certificate of Incorporation (the “Certificate”), but including any other shares of Common Stock issued upon conversion of such Preferred Stock)
the right of first refusal to purchase, at minimum, its Pro Rata Amount (as defined below) of any New Securities (as defined in subsection (a) of this Section 3.1) which the Company may, from time to time, propose to sell and issue. An
Investor’s “Pro Rata Amount,” for purposes of this right of first refusal, shall be the ratio of (i) the number of shares (on an as-converted basis) of Registrable Securities held by such Investor 

  

 -13- 

 
before the offering of New Securities (excluding, for this purpose, all Forced Conversion Shares) to (ii) the total number of outstanding shares (on an
as-converted basis) of Common Stock before the offering of New Securities, including for this purpose all Forced Conversion Shares, all other Conversion Shares and all other outstanding securities convertible into, exchangeable for or exercisable
for Common Stock on an as-converted or exercised basis. This right of first refusal shall be subject to the following provisions: 
  
 (a) “New Securities” shall mean any capital stock of the Company whether or not now authorized, the rights, options or warrants to purchase
capital stock and securities of any type whatsoever that are, or may become, convertible into capital stock; provided, however, that the term “New Securities” does not include any Exempt Issuances. 
  
 (b) In the event the Company proposes to undertake an issuance of New
Securities, it shall give each Investor written notice of its intention, describing the type of New Securities, the price and number of shares and the general terms upon which the Company proposes to issue the same. Each Investor shall have twenty
(20) days from the date of receipt of any such notice to agree to purchase up to the amount of New Securities equal to the Investor’s Pro Rata Amount of such New Securities, for the price and upon the general terms specified in the notice, by
giving written notice to the Company. Each Investor shall have a right of over-allotment such that if any Investor fails to exercise its right hereunder to purchase all of such Investor’s Pro Rata Amount of New Securities, the Company shall
notify the other Investor(s) exercising their rights to purchase their full Pro Rata Amount and such other Investor(s) shall have the right to purchase the non-fully-participating Investor’s unpurchased portion on a pro rata basis (based upon
the ratio of the number of shares (on an as-converted basis) of Registrable Securities held by each such Investor to the total number of outstanding shares (on an as-converted basis) of Registrable Securities held by all fully-participating
Investors), by agreeing to purchase such amount of New Securities within ten (10) days from the date such notice shall have been deemed given under Section 5.4. 
  

(c) In the event an Investor fails to exercise in full the right of first refusal within such twenty (20) day period, or thirty (30) day period in the
event the over-allotment provisions shall be applicable, the Company shall have ninety (90) days thereafter to sell the New Securities for which the Investor’s option was not exercised, at the price and upon the terms specified in the
Company’s notice. In the event the Company has not sold the New Securities within such ninety (90) day period, the Company shall not thereafter issue or sell any New Securities without first offering such securities to the Investors in the
manner provided above. 
  
 SECTION 4 
 INFORMATION RIGHTS 
  
 4.1 Financial Statements. As soon as practicable after the end of each fiscal year of the Company, the Company shall deliver to each
Investor which holds at least 1,000,000 shares of Registrable Securities, and in any event within 90 days thereafter, an audited consolidated balance sheet of the Company as of the end of such year and audited consolidated statements of income,
shareholders’ equity and cash flows for such year, which year-end financial reports shall be in reasonable detail and shall be prepared in accordance with generally accepted accounting principles and be accompanied by the opinion of independent
public accountants of recognized standing selected by the Board of Directors of the Company. 
  

 -14- 

 4.2 Additional Information. The Company shall deliver to each Investor which holds at least
1,000,000 shares of Registrable Securities: 
  
 (a) As soon as
practicable after the end of each month and quarter, and in any event within 30 days and 45 days thereafter, respectively, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such period, and consolidated
statements of income and cash flow for such period and for the current fiscal year to date, including a comparison between the actual period financial statements and the projected figures for such periods. 
  
 (b) As soon as practicable following submission to and approval by the Board
of Directors of the Company, but in no event later than 30 days prior to the beginning of each fiscal year, an operating budget and plan for the Company respecting the next fiscal year containing a monthly breakdown of income and cash flow.

  
 (c) As soon as practicable after the end of each fiscal
quarter, and in any event within 45 days thereafter, a statement of shareholders’ equity as of the end of such fiscal quarter and a statement showing the number of shares of each class and series of capital stock and securities convertible into
or exercisable for shares of capital stock outstanding at the end of the period, the number of shares of Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for shares of Common Stock and the
exchange ratio or exercise price applicable thereto, all in sufficient detail as to permit the Investor to calculate its percentage equity ownership in the Company. 
  
 (d) As soon as practicable after receipt, notification of the filing of any material litigation against the Company.

  
 (e) As soon as practicable after filing, copies of all
filings made by the Company with the Commission. 
  
 4.3
Inspection. The Company shall permit each Investor which holds at least 1,000,000 shares of Registrable Securities, at such Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and
records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by each such Investor; provided, however, that the Company shall not be obligated pursuant to
this Section 4 to provide any information which it reasonably considers to be a trade secret or confidential information. 
  
 4.4 Observation Rights. The Company shall permit each Investor which holds at least 1,000,000 shares of Registrable Securities, at such
Investor’s expense, to attend Board meetings. The Company shall notify and provide meeting materials to each qualifying Investor at the same time such notice and materials are provided to the members of the Board. Board observers pursuant to
this Section 4.4 shall have no power to vote at Board meetings. 
  

 -15- 

 4.5 Transferability of Information Rights. The rights of an Investor under this Section 4
may not be assigned as part of such Investor’s sale of any of the Registrable Securities except with the consent of the Company, which consent shall not be unreasonably withheld, or as set forth in Section 5.11. 
  
 SECTION 5 
 COVENANTS OF DADE BEHRING 
  
 5.1 Certain Definitions. As used in this Section 5: 
  
 (a) The term “Voting Stock” means the Common Stock, Preferred Stock and any other securities issued by the Company having the power to vote in
the election of directors of the Company (other than securities having such power only upon the happening of a contingency). 
  
 (b) The term “Total Voting Power” means the total number of votes that may be cast in the election of directors of the Company at any meeting
of stockholders of the Company if all securities entitled to vote in the election of directors of the Company were present and voted at such meeting (other than votes that may be cast only upon the happening of a contingency). For this purpose,
Total Voting Power shall be deemed to include shares issuable upon exercise of outstanding options and options not yet issued but authorized under the Company’s 1997 Stock Plan and similar plans. 
  
 5.2 Voting Trust, etc. Dade Behring shall not deposit any
shares of Voting Stock held by Dade Behring in a voting trust or, except as otherwise provided in this Agreement, subject any Voting Stock to any arrangement or agreement with respect to the voting of such Voting Stock. 
  
 5.3 Solicitation of Proxies. Without the Company’s prior
written consent, Dade Behring shall not solicit proxies with respect to any Voting Stock nor shall it become a “participant” in any “election contest” (as such terms are used in Rule 14a-11 of Regulation 14A under the Exchange
Act) relating to the election of directors of the Company; provided, however, that Dade Behring shall not be deemed to be a “participant” by reason of the membership on the Company’s board of directors of any member elected by Dade
Behring and Dade Behring shall not be restricted from voting its Voting Stock on any matter in its discretion nor from advising other stockholders of how Dade Behring intends to vote on any matter. 
  
 5.4 Acts in Concert with Others. Dade Behring shall not join a
partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding, or disposing of Voting Stock; provided, however, that Dade Behring shall not be restricted from voting its Voting Stock on any matter in its discretion
or from advising other stockholders of how Dade Behring intends to vote on any matter, or from disposing of its Voting Stock in any transaction approved by the stockholders. 
  
 5.5 Acquisition of Additional Voting Stock. Until the date that is ten years after October 5, 2000, Dade
Behring shall not acquire beneficial ownership of any additional Voting Stock, any securities convertible into or exchangeable for Voting Stock, or any other right to acquire 

  

 -16- 

 
Voting Stock (except by way of stock dividends or other distributions or offerings made available to holders of any Voting Stock generally or to Dade Behring
pursuant to its rights under the Investor Rights Agreement, as amended) without the written consent of the Company, if the effect of such acquisition would be to increase the Voting Power of all Voting Stock then owned by Dade Behring, or that it
has a right to acquire, to more than 30% of the Total Voting Power of the Company at such time (or, if Dade Behring already holds or has the right to acquire more than 30% of the Total Voting Power, to increase the number of shares of Voting Stock
that it holds or has rights to acquire); provided, however, that: 
  
 (a) Dade Behring may acquire Voting Stock (or rights to acquire Voting Stock) without regard to the limitations in this Section 5.5 if it is publicly disclosed or Dade Behring otherwise learns that another person or group has acquired any
Voting Stock (or rights to acquire Voting Stock) that results, or has entered into an agreement with the Company that would result, in such person or group owning or having the right to acquire Voting Stock with aggregate Voting Power of more than
30% of the Total Voting Power of the Company at such time. 
  
 (b) Dade Behring may acquire Voting Stock without regard to the limitations in this Section 5.5 if a tender offer is made (as evidenced by the filing with the SEC of a Schedule 14D-1 (or any successor schedule or form promulgated or adopted
for such purpose by the SEC) and the actual dissemination of tender offer materials to security holders) by another person or group to purchase or exchange for cash or other consideration any Voting Stock that, if successful, would result in such
person or group owning or having the right to acquire shares of Voting Stock with aggregate Voting Power of at least 40% of the Total Voting Power of the Company at such time. This clause (b) shall not be effective until such time as Dade Behring,
in the exercise of the reasonable judgment of its Board of Directors, after consultation with its investment bankers and those of the Company (who shall make themselves promptly available), shall reasonably conclude that such tender offeror can
finance such tender offer. 
  
 (c) Dade Behring will not be
obligated to dispose of any shares of Voting Stock if Dade Behring’s aggregate percentage ownership is increased as a result of a recapitalization of the Company or a repurchase of securities by the Company or any other action taken by the
Company or its affiliates, but Dade Behring shall not acquire any additional Voting Stock unless such acquisition would otherwise be permitted under this Section 5.5. 
  
 Dade Behring shall advise management of the Company as to Dade Behring’s plans to acquire additional shares of Voting Stock, or rights
thereto, reasonably in advance of any such acquisition. All purchases by Dade Behring of the Company’s securities shall be made in compliance with applicable laws and regulations. 
  
 5.6 Restrictions on Transfer of Voting Stock. Dade Behring shall not, directly or indirectly, sell or transfer
any Voting Stock except (a) to the Company or any person or group approved by the Company; or (b) to a corporation of which Dade Behring owns not less than 80% of the voting power entitled to be cast in such corporation’s election of directors
(a “Controlled Corporation”), so long as such Controlled Corporation agrees to hold such Voting Stock subject to all the provisions of this Agreement, including this Section 5.6, and agrees to transfer such Voting 

  

 -17- 

 
Stock to Dade Behring or another Controlled Corporation of Dade Behring if such corporation ceases to be a Controlled Corporation of Dade Behring; or (c)
pursuant to a bona fide public offering (which shall be structured to distribute such shares or rights through an underwriter or otherwise in such a manner as should not result in beneficial ownership of Voting Stock with aggregate Voting Power of
5% or more of the Total Voting Power of the Company at such time being transferred to a single person or group), registered under the Securities Act, of either Voting Stock or securities exchangeable or exercisable for Voting Stock or pursuant to a
rights offering or a dividend or other distribution to stockholders of Dade Behring; or (d) pursuant to Rule 144 under the Securities Act (excluding Rule 144(k)); or (e) in transactions not otherwise described herein so long as such transactions do
not, directly or indirectly, result, to the best knowledge of Dade Behring, after reasonable inquiry, in any single person or group owning or having the right to acquire Voting Stock with aggregate Voting Power of 5% or of the Total Voting Power of
the Company at such time; or (f) in response to (1) an offer to purchase or exchange for cash or other consideration any Voting Stock (A) that is made by or on behalf of the Company, or (B) that is made by another person or group and is not opposed
by the Board of Directors of the Company within the time such Board is required, pursuant to regulations under the Exchange Act, to advise the Company’s stockholders of such Board’s position on such offer, or (2) any other offer made by
another person or group to purchase or exchange for cash or other consideration any Voting Stock that, if successful, would result in such person or group owning or having the right to acquire Voting Stock with aggregate Voting Power of more than
40% of the Total Voting Power of the Company at such time; or (g) pursuant to a bona fide pledge of such Voting Stock to an institutional lender to secure a loan, guarantee or other financial support, provided that such lender agrees to hold such
Voting Stock subject to all provisions of this Agreement and any sale or disposition by such lender of such pledged Voting Stock shall be subject to the limitations of this Section 5.6, or (h) in the event of a merger or consolidation in which the
holders of Voting Stock of the Company prior to the merger or consolidation cease to hold at least 51% of the Voting Stock of the surviving entity, or (i) pursuant to a plan of liquidation of the Company. 
  
 5.7 Series C Preferred Stock Purchase Agreement. The Company
and Dade Behring hereby acknowledge and agree that Sections 7 and 8 of the Series C Preferred Stock Purchase Agreement dated October 5, 2000 (as amended, restated, modified or otherwise supplemented, the “Series C Purchase Agreement”) have
been terminated and are no longer of any force or effect. The Company and Dade Behring hereby agree that if at any time after the Closing Date, any further action is necessary or desirable to terminate the provisions of Sections 7 and 8 of the
Series C Purchase Agreement, the officers and directors of the Company are fully authorized in the name of the Company or otherwise to take, and will take, all such lawful and necessary action. 
  
 SECTION 6 
 MISCELLANEOUS 
  
 6.1 Termination. Unless earlier terminated by an agreement among the Investors holding a majority of the Preferred Stock and the holders of Common Stock, the terms of Sections 3, 4 and 5 shall terminate
immediately prior to the closing of the Company’s Initial Public Offering. 
  

 -18- 

 6.2 Governing Law. This Agreement shall be governed and construed in all respects in
accordance with the laws of the State of Delaware as applied to agreements made and performed in Delaware by residents of the State of Delaware. 
  
 6.3 Entire Agreement; Amendment. This Agreement constitutes the entire understanding and agreement between the parties with regard to the
subjects hereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein. Except as expressly provided herein, neither this Agreement nor any term
hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought; provided, however, that holders
of a majority of the Registrable Securities may, with the Company’s prior written consent, waive, modify or amend on behalf of all Holders any provisions hereof. 
  
 6.4 Notices. All notices and other communications required or permitted hereunder shall be in writing and
shall be mailed by registered or certified mail, postage prepaid, sent by overnight courier, transmitted by facsimile or otherwise delivered by hand or by messenger, addressed (a) if to an Investor, at such Investor’s address set forth on an
exhibit hereto, or at such other address as such Investor shall have furnished to the Company in writing, with a copy to: 
  
 Orrick, Herrington & Sutcliffe LLP 
 719
Second Avenue, Suite 900 
 Seattle, WA 98104 
 Attn: Alan C. Smith 
  
 (b) if to the Company, to:

  
 HemoSense, Inc. 
 651 River Oaks Pkwy 
 San Jose, CA 95134

 Attn: Corporate Secretary 
  
 or at such other address as the Company shall have furnished to the Investors, with a copy to: 
  
 Michael J. Danaher, Esq. 
 Wilson Sonsini Goodrich & Rosati 
 650 Page Mill Road 
 Palo Alto, CA 94304 
  
 Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when delivered if delivered
personally, or if sent by mail, at the earlier of its receipt and 72 hours after the same has been deposited in a regularly maintained receptacle for the deposit of the United States mail, or if sent by overnight courier, at the earlier of its
receipt and 24 hours after the same has been deposited with a reputable carrier, or if transmitted by facsimile, upon confirmation of receipt, addressed and mailed as aforesaid. 
  

 -19- 

 6.5 Severability. In the event that any provision of this Agreement becomes or is declared
by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic
benefit of this Agreement to any party. 
  
 6.6 Titles and
Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or interpreting this Agreement. 
  
 6.7 Adjustments for Stock Splits, Etc. Wherever in this Agreement there is a reference to a specific number of
shares of Common Stock or Preferred Stock of the Company of any class or series, then, upon the occurrence of any subdivision, combination or stock dividend of such class or series of stock, the specified number of shares so referenced in this
Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class or series of stock by such subdivision, combination or stock dividend. 
  
 6.8 Aggregation of Stock. All shares held or acquired by an
Affiliate, as defined in Section 2.11, or affiliated Persons, including members of a limited liability company, shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 6.9 Counterparts. This Agreement may be executed in any number
of counterparts, each of which may be executed by less than all of the Investors, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 
  
 6.10 Reservation of Common Stock. The Company shall reserve and
maintain a sufficient number of shares of Common Stock for issuance upon conversion of all the Shares at any time outstanding. 
  
 6.11 Transfer of Rights. The right of first refusal set forth in Section 3 and the rights to information under Section 4 may be assigned by
any Holder to a transferee or assignee of any Registrable Securities that is an Affiliate (as defined in Section 2.11), partner, member or shareholder of any Holder, including any entity controlling, under common control with or controlled by such
Investor who acquires from such Investor any shares of Preferred Stock; provided, however, that (a) the Company must receive written notice prior to the time of such transfer, stating the name and address of such transferee or assignee
and identifying the securities with respect to which such information and Registration Rights are being assigned, and (b) the transferee or assignee of such rights must not be a Person who is a competitor or potential competitor of the Company, as
determined in good faith by the Board of Directors of the Company. Any Holder may transfer such Holder’s Registration Rights pursuant to the assignment provision in Section 2.11 hereof. 
  
 6.12 Expenses of Directors. The Company shall promptly
reimburse in full each director of the Company who is not an employee of the Company for all such director’s reasonable travel and lodging expenses incurred pursuant to his or her attendance at Board of Directors and Committee meetings and for
other services he or she may render on behalf of the Company in his or her capacity as a director. 
  

 -20- 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investor Rights Agreement as of
the date first above written. 
  

			
	HEMOSENSE, INC.
		
	By:	 	 /s/ JAMES MERSELIS

	 	 	James Merselis
	 	 	Chief Executive Officer

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES A-2 INVESTORS: 
  

	
	 WS Investment Company, LLC (97B)

	(Please print name)
	
	 /s/    MICHAEL J. DANAHER        

	(Signature)
	
	 Member

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES B-2 INVESTORS: 
  

	
	 Michael J. Danaher

	(Please print name)
	
	 /s/ MICHAEL J. DANAHER

	(Signature)
	
	  

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES B-2 INVESTORS: 
  

	
	 WS Investment Company, LLC (99A)

	(Please print name)
	
	 /s/ MICHAEL J. DANAHER

	(Signature)
	
	 Member

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES C-2 INVESTORS: 
  

	
	 Michael J. Danaher

	(Please print name)
	
	 /s/ MICHAEL J. DANAHER

	(Signature)
	
	  

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES C-2 INVESTORS: 
  

	
	 WS Investment Company, LLC

	(Please print name)
	
	 /s/ MICHAEL J. DANAHER

	(Signature)
	
	 Member

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 SERIES C-2 INVESTORS: 
  

	
	 WS Investment Company, LLC (2003A)

	(Please print name)
	
	 /s/ MICHAEL J. DANAHER

	(Signature)
	
	 Member

	(Title, if applicable)

  
 [Signature
Page to HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

			
	SERIES C-3 INVESTORS:	 	 B.F. SAUL COMPANY EMPLOYEES’
 PROFIT SHARING
RETIREMENT TRUST

		
	 	 	 /s/ ALEXANDER R.M. BOYLE

	 	 	(Signature)
		
	 	 	  

	 	 	(Print Name and Title)
		
	 	 	CONNECTICUT AVENUE INVESTMENTS, L.L.C.
		
	 	 	 /s/ STEPHEN HALPIN

	 	 	(Signature)
		
	 	 	  

	 	 	(Print Name and Title)
		
	 	 	MICHAEL J. DANAHER
		
	 	 	 /s/ MICHAEL J. DANAHER

	 	 	(Signature)
		
	 	 	ARVIND JINA
		
	 	 	 /s/ ARVIND JINA

	 	 	(Signature)

  
 [Signature Page to
HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

					
	SERIES C-3 INVESTORS:	 	MPM BIOVENTURES II, L.P.
			
	 	 	By:	 	MPM Asset Management II, L.P., its General Partner
	 	 	By:	 	MPM Asset Management II LLC, its General Partner
			
	 	 	By:	 	 /s/ KURT C. WHEELER

	 	 	Name:	 	Kurt C. Wheeler
	 	 	Title:	 	Investment Manager
		
	 	 	MPM BIOVENTURES II-QP, L.P.
			
	 	 	By:	 	MPM Asset Management II, L.P., its General Partner
	 	 	By:	 	MPM Asset Management II LLC, its General Partner
			
	 	 	By:	 	 /s/ KURT C. WHEELER

	 	 	Name:	 	Kurt C. Wheeler
	 	 	Title:	 	Investment Manager
		
	 	 	MPM BIOVENTURES GMBH & CO. PARALLEL-BETEILIGUNGS KG
			
	 	 	By:	 	MPM Asset Management II, L.P., in its capacity as the Special Limited Partner
	 	 	By:	 	MPM Asset Management II LLC, its General Partner
			
	 	 	By:	 	 /s/ KURT C. WHEELER

	 	 	Name:	 	Kurt C. Wheeler
	 	 	Title:	 	Investment Manager
		
	 	 	MPM ASSET MANAGEMENT INVESTORS 2000 B LLC
			
	 	 	By:	 	 /s/ KURT C. WHEELER

	 	 	Name:	 	Kurt C. Wheeler
	 	 	Title:	 	Investment Manager

  
 [Signature Page to
HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

					
	SERIES C-3 INVESTORS:	 	 VANGUARD V, L.P.

		
	 	 	 /s/ ROBERT D. ULRICH

	 	 	 (Signature)

	 	 	  

	 	 	 (Print Name and Title)

		
	 	 	 W CAPITAL PARTNERS IRONWORKS, L.P.

			
	 	 	 By:
	 	 WCP I, LLC

			
	 	 	 By:
	 	 /s/ ROBERT J. MIGLIORINO

		
	 	 	 WS INVESTMENT COMPANY, LLC

		
	 	 	 /s/ MICHAEL J. DANAHER

	 	 	 (Signature)

		
	 	 	 Member

	 	 	 (Print Name and Title)

  
 [Signature Page to
HemoSense, Inc. Amended and Restated Investor Rights Agreement] 

 EXHIBIT A 
  

SCHEDULE OF SERIES A-2 INVESTORS 
  
 MGVF III, Ltd. 
 777 Post Oak Blvd., Suite 250 
 Houston, TX 77056 
 Attention: Marc Geller 
  
 Vanguard V, L.P. 
 c/o Comventures 
 305 Lytton Avenue 
 Palo Alto, CA 94301 
 Attn: Florence De Leon 
  
 W Capital Partners Ironworks, L.P. 
 c/o W Capital Partners 
 245 Park Ave., 39th Floor 
 New York, NY 10167 
 Attn: Robert J. Migliorino MGVF III, Ltd. 
  
 WS Investment Company, LLC (97B) 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attn: Jim Terranova 

 EXHIBIT B 
  

SCHEDULE OF SERIES B-2 INVESTORS 
  
 Dade Behring, Inc. 
 1717 Deerfield Road 
 Deerfield, IL 60015 
 Attn: Louise Pearson 
  
 Michael J. Danaher 
 650 Page Mill Road 
 Palo Alto, CA 94304 
  
 G.C. Technology Fund, L.P. 
 777 Post Oak Blvd.,
Suite 250 
 Houston, TX 77056 
 Attention: Marc Geller

  
 Vanguard V, L.P. 
 c/o Comventures 
 305 Lytton Avenue 
 Palo Alto, CA 94301 
 Attn: Florence De Leon 
  
 W Capital Partners Ironworks, L.P. 
 c/o W Capital Partners 
 245 Park Ave., 39th Floor 
 New York, NY 10167 
 Attn: Robert J. Migliorino 
  
 WS Investment Company, LLC (99A) 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attn: Jim Terranova 

 EXHIBIT C 
  

SCHEDULE OF SERIES C-2 INVESTORS 
  
 B.F. Saul Company Employees’ Profit Sharing Retirement Trust 
 c/o BF
Saul Company 
 7501 Wisconsin Avenue, Suite 1500 
 Bethesda, MD
20814-6522 
 Attn: Henry Ravenel 
  
 Connecticut Avenue Investments, LLC 
 c/o Chevy Chase Bank 
 7501 Wisconsin Avenue, Suite 1500 
 West Tower 
 Bethesda, MD 20814-6522 
 Attn: Steve Halpin 
  
 Dade Behring, Inc. 
 1717 Deerfield Road 
 Deerfield, IL 60015 
 Attn: Louise Pearson 
  
 Michael J. Danaher

 650 Page Mill Road 
 Palo Alto, CA 94304 
  
 G.C. Technology Fund, L.P. 
 777 Post Oak Blvd., Suite 250 
 Houston, TX 77056 
 Attention: Marc Geller 
  
 Arvind Jina 

3353 Colonna Avenue 
 San Jose, CA 95148 
  
 MGVF III, Ltd. 
 777 Post Oak Blvd., Suite 250 
 Houston, TX 77056 
 Attention: Marc Geller 

 MPM Bioventures GmbH & Co. 
 Parallel-Beteiligungs KG 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 MPM Bioventures II, L.P. 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 MPM Bioventures II-QP, L.P. 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 MPM Asset Management
Investors 2000 B LLC 
 601 Gateway Blvd., Suite 350 
 So. San
Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 Vanguard V, L.P. 
 c/o Comventures 
 305 Lytton Avenue 
 Palo Alto, CA 94301 
 Attn: Florence De Leon 
  
 W Capital Partners Ironworks, L.P. 
 c/o W Capital Partners 
 245 Park Ave., 39th Floor 
 New York, NY 10167 
 Attn: Robert J. Migliorino 
  
 WS Investment
Company, LLC (2003A) 
 650 Page Mill Road 
 Palo Alto, CA 94304

 Attn: Jim Terranova 
  
 WS Investment Company, LLC 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attn: Jim Terranova 

 EXHIBIT D 
  

SCHEDULE OF SERIES C-3 INVESTORS 
  
 B.F. Saul Company Employees’ Profit Sharing Retirement Trust 
 7501
Wisconsin Avenue 
 Suite 1500 East 
 Bethesda, Maryland
20814-6522 
  
 Connecticut Avenue Investments, L.L.C. 
 c/o Stephen Halpin 
 7501 Wisconsin Avenue 
 Suite 1500 West 
 Bethesda, Maryland 20814-6522 
  
 Michael J. Danaher 
 650 Page Mill Road 
 Palo Alto, California 94304 
  
 Arvind Jina 
 3353 Colonna Avenue 
 San Jose, CA 95148 
  
 MPM Bioventures GmbH & Co. 
 Parallel-Beteiligungs KG 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 MPM Bioventures II,
L.P. 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080

 Attention: Kurt Wheeler 
  
 MPM Bioventures II-QP, L.P. 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 

 MPM Asset Management Investors 2000 B LLC 
 601 Gateway Blvd., Suite 350 
 So. San Francisco, CA 94080 
 Attention: Kurt Wheeler 
  
 Vanguard V, L.P.

 525 University Avenue, Suite 600 
 Palo Alto, CA 94301

 Attention: Dr. Robert Ulrich 
  
 W Capital Partners Ironworks, L.P. 
 c/o W Capital Partners 
 245 Park Ave., 39th Floor 
 New York, NY 10167 
 Attn: Robert J. Migliorino 
  
 WS Investment Company, LLC 
 650 Page Mill Rd. 
 Palo Alto, CA 94034 
 Attn: Jim TerranovaForm of Indemnification Agreement

 Exhibit 10.1 
  
 HEMOSENSE, INC. 
  
 INDEMNIFICATION AGREEMENT 
  
 This Indemnification Agreement (“Agreement”) is made as of this          day of
                    ,             , by and between HemoSense, Inc., a
Delaware corporation (the “Company”), and                      (“Indemnitee”). 
  
 WHEREAS, the Company and Indemnitee recognize the significant
cost of directors’ and officers’ liability insurance and the general reductions in the coverage of such insurance; 
  
 WHEREAS, the Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting officers and
directors to expensive litigation risks at the same time as the coverage of liability insurance has been severely limited; and 
  
 WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve as officers
and directors of the Company and to indemnify its officers and directors so as to provide them with the maximum protection permitted by law. 
  
 NOW, THEREFORE, in consideration for Indemnitee’s services as an officer or director of the Company, the Company and Indemnitee hereby
agree as follows: 
  
 1. Indemnification.

  
 (a) Third Party Proceedings. The Company shall
indemnify Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit, proceeding or any alternative dispute resolution mechanism, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason of the fact that Indemnitee
is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts
paid in settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit or proceeding if Indemnitee acted in
good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s conduct was
unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith
and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that Indemnitee’s conduct was unlawful.

 (b) Proceedings By or in the Right of the Company. The Company shall indemnify Indemnitee if
Indemnitee was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company or any subsidiary of the Company to procure a judgment in its favor by reason of the fact that
Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) and, to the fullest extent permitted by law, amounts paid in settlement actually and reasonably incurred by Indemnitee in
connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, except that no indemnification shall be
made in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Company unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was
brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the
State of Delaware or such other court shall deem proper. 
  
 (c)
Mandatory Payment of Expenses. To the extent that Indemnitee has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Subsections (a) and (b) of this Section 1, or in defense of any claim,
issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by Indemnitee in connection therewith. 
  
 2. Expenses; Indemnification Procedure. 
  
 (a) Advancement of Expenses. The Company shall advance all expenses incurred by Indemnitee in connection with the
investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referenced in Section 1(a) or (b) hereof (but not amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby
undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby. The advances to be made hereunder shall be paid by
the Company to Indemnitee within thirty (30) days following delivery of a written request therefor by Indemnitee to the Company. 
  
 (b) Notice/Cooperation by Indemnitee. Indemnitee shall, as a condition precedent to his right to be indemnified under this Agreement, give the
Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the President of the Company at the address
shown on the signature page of this Agreement (or such other address as the Company 
  

 - 2 - 

 shall designate in writing to Indemnitee). Notice shall be deemed received three business days after the date postmarked
if sent by domestic certified or registered mail, properly addressed, five business days if sent by airmail to a country outside of North America; otherwise notice shall be deemed received when such notice shall actually be received by the Company.
In addition, Indemnitee shall give the Company such information and cooperation as it may reasonably require and as shall be within Indemnitee’s power. 
  
 (c) Procedure. Any indemnification and advances provided for in Section 1 and this Section 2 shall be made no later than thirty (30) days after
receipt of the written request of Indemnitee. If a claim under this Agreement, under any statute, or under any provision of the Company’s Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company
within thirty (30) days after a written request for payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and,
subject to Section 12 of this Agreement, Indemnitee shall also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a
claim for expenses incurred in connection with any action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify
Indemnitee for the amount claimed. However, Indemnitee shall be entitled to receive interim payments of expenses pursuant to Subsection 2(a) unless and until such defense may be finally adjudicated by court order or judgment from which no further
right of appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide, and neither the failure
of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances
because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including it Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or
its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. 
  
 (d) Notice to Insurers. If, at the time of the receipt of a notice of a claim pursuant to Section 2(b) hereof, the
Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 
  
 (e) Selection of Counsel. In the event the Company shall be obligated
under Section 2(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the delivery to Indemnitee of
written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the 
  

 - 3 - 

 Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred
by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall have the right to employ his counsel in any such proceeding at Indemnitee’s expense; and (ii) if (A) the employment of counsel by Indemnitee has been
previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C) the Company shall not, in fact, have employed
counsel to assume the defense of such proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company. 
  
 3. Additional Indemnification Rights; Nonexclusivity. 
  
 (a) Scope. Notwithstanding any other provision of this Agreement, the Company hereby agrees to indemnify the
Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company’s Certificate of Incorporation, the Company’s Bylaws or by
statute. In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes shall be,
ipso facto, within the purview of Indemnitee’s rights and Company’s obligations, under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify
a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties’ rights and obligations
hereunder. 
  
 (b) Nonexclusivity. The indemnification
provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested Directors, the
General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee’s official capacity and as to action in another capacity while holding such office. The indemnification provided under this Agreement shall continue
as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he may have ceased to serve in such capacity at the time of any action, suit or other covered proceeding. 
  
 4. Partial Indemnification. If Indemnitee is entitled under any
provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred by him in the investigation, defense, appeal or settlement of any civil or criminal
action, suit or proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled. 
  
 5. Mutual Acknowledgement. Both the Company and Indemnitee
acknowledge that in certain instances, Federal law or applicable public policy may prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges that the Company has
undertaken or may be required in the future to undertake 
  

 - 4 - 

 with the Securities and Exchange Commission to submit the question of indemnification to a court in certain circumstances
for a determination of the Company’s right under public policy to indemnify Indemnitee. 
  
 6. Officer and Director Liability Insurance. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or
policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this
Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as
an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a
director of the Company but is an officer. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the
premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance
maintained by a subsidiary or parent of the Company. 
  
 7.
Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform
its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 7. If this Agreement or any portion hereof shall be invalidated on any ground by
any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so
invalidated shall be enforceable in accordance with its terms. 
  
 8. Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement: 
  
 (a) Claims Initiated by Indemnitee. To indemnify or advance expenses to Indemnitee with respect to proceedings or
claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law or otherwise as required
under Section 145 of the Delaware General Corporation Law, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors has approved the initiation or bringing of such suit; or

  
 (b) Lack of Good Faith. To indemnify Indemnitee for any
expenses incurred by the Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by the Indemnitee in such
proceeding was not made in good faith or was frivolous; or 
  

 - 5 - 

 (c) Insured Claims. To indemnify Indemnitee for expenses or liabilities of any type whatsoever
(including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) which have been paid directly to Indemnitee by an insurance carrier under a policy of officers’ and directors’ liability
insurance maintained by the Company. 
  
 (d) Claims Under
Section 16(b). To indemnify Indemnitee for expenses and the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar
successor statute. 
  
 9. Construction of Certain
Phrases. 
  
 (a) For purposes of this Agreement,
references to the “Company” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had
continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request
of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect
to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. 
  
 (b) For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company
which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

  
 10. Counterparts. This Agreement may be executed
in one or more counterparts, each of which shall constitute an original. 
  
 11. Successors and Assigns. This Agreement shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of Indemnitee and Indemnitee’s estate, heirs, legal
representatives and assigns. 
  
 12. Attorneys’ Fees.
In the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’ fees,
incurred by Indemnitee with respect 
  

 - 6 - 

 to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material
assertions made by Indemnitee as a basis for such action were not made in good faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee’s counterclaims and cross-claims made in
such action), unless as a part of such action the court determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous. 
  
 13. Notice. All notices, requests, demands and other communications under this Agreement shall be in writing
and shall be deemed duly given (i) if delivered by hand and receipted for by the party addressee, on the date of such receipt, or (ii) if mailed by domestic certified or registered mail with postage prepaid, on the third business day after the date
postmarked. Addresses for notice to either party are as shown on the signature page of this Agreement, or as subsequently modified by written notice. 
  
 14. Consent to Jurisdiction. The Company and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of
Delaware for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement and agree that any action instituted under this Agreement shall be brought only in the state courts of the State of Delaware.

  
 15. Choice of Law. This Agreement shall be
governed by and its provisions construed in accordance with the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware without regard to the conflict of law
principles thereof. 
  
 16. Period of Limitations.
No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of two years
from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however,
that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter period shall govern. 
  
 17. Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the
rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights. 
  
 18. Amendment and Termination. No amendment, modification,
termination or cancellation of this Agreement shall be effective unless it is in writing signed by both the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions
hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 
  

 - 7 - 

 19. Integration and Entire Agreement. This Agreement sets forth the entire understanding
between the parties hereto and supersedes and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto 
  

 - 8 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

  

			
	HEMOSENSE, INC.
	  
  

	Signature of Authorized Signatory
	  
  

	Print Name and Title
		
	Address:	  	651 River Oaks Parkway
	 	  	San Jose, CA 95134

  

			
	AGREED TO AND ACCEPTED:
	
	INDEMNITEE:
	  
  

	Signature
	  
  

	Print Name and Title
		
	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]